EXTON, Pa.--(BUSINESS WIRE)--Morphotek®, Inc., a subsidiary of Eisai Co., Ltd., today announced that it has commenced a multi-centered Phase II study of its MORAb-009 monoclonal antibody. The study will evaluate MORAb-009, plus the chemotherapy drug gemcitabine, as a first line treatment for patients with pancreatic cancer. The randomized, controlled, double-blinded trial will compare MORAb-009 plus gemcitabine with a placebo plus gemcitabine.
